<DOC>
	<DOCNO>NCT02590432</DOCNO>
	<brief_summary>The primary objective study assess potential linaclotide treatment induce development anti-drug antibody ( ADAs ) . The secondary objective provide additional evidence support long-term safety efficacy linaclotide adult irritable bowel syndrome constipation ( IBS-C ) chronic idiopathic constipation ( CIC ) patient evaluate low dos linaclotide .</brief_summary>
	<brief_title>An Open-Label , Long-term Study Assess Immunogenicity Linaclotide Administered Orally Adult Patients With Irritable Bowel Syndrome With Constipation Chronic Idiopathic Constipation</brief_title>
	<detailed_description>This study include 3-week Screening Period , follow 52-week treatment period . Patients CIC meeting entry criterion receive linaclotide 145-ug capsule , orally , daily patient IBS-C meeting entry criterion receive linaclotide 290-ug capsule , orally , daily .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patients meet Rome III criterion IBSC CIC : IBSC Criteria : patient must meet follow 2 criterion ( A B ) A. IBS Criteria : The patient must abdominal pain discomfort least 3 day per month 3 month diagnosis ( symptom onset least 6 month diagnosis ) associate 2 following : 1 . Improvement defecation 2 . Onset associate change frequency stool 3 . Onset associate change form ( appearance ) stool B. Stool Consistency Requirement : During 3 month diagnosis absence laxative enema use , patient hard lumpy stool ( Bristol Stool Form Scale [ BSFS ] score 1 2 ) least 25 % BMs loose mushy stool ( BSFS 5 6 ) &lt; 25 % BMs CIC Criteria : patient must meet follow 3 criterion ( A , B , C ) : A . Patient meet 2 follow criterion 3 month diagnosis symptom onset least 6 month diagnosis : 1 . Straining least 25 % defecation 2 . Lumpy hard stool least 25 % defecation 3 . Sensation incomplete evacuation least 25 % defecation 4 . Sensation anorectal obstruction/blockage least 25 % defecation 5 . Manual maneuver facilitate least 25 % defecation ( eg , digital evacuation , support pelvic floor ) 6 . Fewer 3 defecation per week B . Loose stool rarely present without use laxative C. Insufficient criterion irritable bowel syndrome . ( The criterion IBS provide Point A IBS Criteria , ) Patient meet colonoscopy requirement , modify Summary USMultiSociety Task Force Colorectal Cancer Colonoscopy Requirements Patient successfully complete protocol procedure ( clinically significant finding ) At Day 1 visit , patient report 6 spontaneous bowel movement ( SBMs ) week prior screen . At Day 1 visit , patient report SBMs watery ( BSFS=7 ) 1 SBM mushy ( BSFS=6 ) week prior screen . Patient structural abnormality gastrointestinal ( GI ) tract disease condition affect GI motility . Patient protocol exclude clinically significant medical surgical history would limit patient 's ability complete participate clinical trial could confound study assessment . Patient ever receive linaclotide treatment ( include commerciallyavailable product ) randomize clinical study linaclotide treatment . ( Patients enrol linaclotide clinical study conduct prior study fail randomize eligible current study ) . Patient ever receive plecanatide , SP333 , participate plecanatide clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Irritable Bowel Syndrome Constipation</keyword>
	<keyword>Chronic Idiopathic Constipation</keyword>
	<keyword>Linaclotide</keyword>
	<keyword>Linzess</keyword>
</DOC>